DANBURY, Conn.--(BUSINESS WIRE)--IMS Health (NYSE:IMS), a leading global provider of information and technology services to the healthcare and life sciences industries, today completed its previously announced acquisition of certain customer relationship management (CRM) and strategic data businesses of Cegedim.
The acquisition gives IMS Health powerful new tools to address growing demand for end-to-end CRM, multi-channel marketing and master data management solutions. It also establishes one of the world’s most robust healthcare reference databases with insights on more than 14 million healthcare professionals, and solidifies IMS Health as the partner of choice for Real-World Evidence capabilities.
“Most importantly, through this acquisition we are thrilled to welcome more than 4,500 new IMSers – highly skilled professionals with deep technology and healthcare expertise,” said Ari Bousbib, chairman and CEO, IMS Health. “Our global team across 100 countries offers an unmatched combination of breadth and depth of capabilities to our 5,000+ clients worldwide.”
About IMS Health
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. End-to-end proprietary applications and configurable solutions connect 10+ petabytes of complex healthcare data through the IMS OneTM cloud-based master data management platform, providing comprehensive insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.